background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

MUC17

Mucin 17 (MUC17) is a member of the mucin family of proteins. Mucins are key components of the mucosal barrier in the gastrointestinal tract that protect epithelia from the carcinogenic effects of chronic inflammation.1,2 MUC17 is a transmembrane protein expressed on the apical membrane of gastrointestinal mucosal epithelial cells, and is highly expressed in a significant number of primary gastric cancers.1,3

GEJ, gastroesophageal junction; HLE, half-life extended.

References
1. van Putten JPM, et al. J Innate Immun. 2017;9:281-299. 2. Kufe DW. Nat Rev Cancer. 2009;9:874-885. 3. Yang B, et al. J Exp Clin Cancer Res. 2019;38:283. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04117958. Accessed 9/22/20.
Molecule
Modality4
Target5
Areas of Investigation4
AMG 199
Target5
MUC17
Areas of Investigation4

GEJ, gastroesophageal junction; HLE, half-life extended.

References
1. van Putten JPM, et al. J Innate Immun. 2017;9:281-299. 2. Kufe DW. Nat Rev Cancer. 2009;9:874-885. 3. Yang B, et al. J Exp Clin Cancer Res. 2019;38:283. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04117958. Accessed 9/22/20.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.